Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,126 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Inflammation and immunogenicity limit the utility of the rabbit as a nonclinical species for ocular biologic therapeutics.
de Zafra CLZ, Sasseville VG, Matsumoto S, Freichel C, Milton M, MacLachlan TK, Farman C, Raymond I, Gupta S, Newton R, Atzpodien EA, Thackaberry EA. de Zafra CLZ, et al. Among authors: newton r. Regul Toxicol Pharmacol. 2017 Jun;86:221-230. doi: 10.1016/j.yrtph.2017.03.013. Epub 2017 Mar 16. Regul Toxicol Pharmacol. 2017. PMID: 28322894
Corrigendum to "Inflammation and immunogenicity limit the utility of the rabbit as a nonclinical species for ocular biologic therapeutics" [Regul. Toxicol. Pharmacol. (2017) 221-230].
de Zafra CLZ, Sasseville VG, Matsumoto S, Freichel C, Milton M, MacLachlan TK, Farman C, Raymond I, Gupta S, Newton R, Atzpodien EA, Thackaberry EA. de Zafra CLZ, et al. Among authors: newton r. Regul Toxicol Pharmacol. 2017 Aug;88:364. doi: 10.1016/j.yrtph.2017.04.006. Epub 2017 Apr 18. Regul Toxicol Pharmacol. 2017. PMID: 28431771 No abstract available.
A Novel Selective Soluble Guanylate Cyclase Activator, MGV354, Lowers Intraocular Pressure in Preclinical Models, Following Topical Ocular Dosing.
Prasanna G, Ferrara L, Adams C, Ehara T, Li B, Yang L, Xiang C, Ng CTH, Kim S, Towler C, Topley T, McAllister C, Ghosh M, Newton R, Stacy R, Rice DS, Mogi M. Prasanna G, et al. Among authors: newton r. Invest Ophthalmol Vis Sci. 2018 Apr 1;59(5):1704-1716. doi: 10.1167/iovs.18-23772. Invest Ophthalmol Vis Sci. 2018. PMID: 29610853
Discovery of Highly Potent and Selective Small-Molecule Reversible Factor D Inhibitors Demonstrating Alternative Complement Pathway Inhibition in Vivo.
Lorthiois E, Anderson K, Vulpetti A, Rogel O, Cumin F, Ostermann N, Steinbacher S, Mac Sweeney A, Delgado O, Liao SM, Randl S, Rüdisser S, Dussauge S, Fettis K, Kieffer L, de Erkenez A, Yang L, Hartwieg C, Argikar UA, La Bonte LR, Newton R, Kansara V, Flohr S, Hommel U, Jaffee B, Maibaum J. Lorthiois E, et al. Among authors: newton r. J Med Chem. 2017 Jul 13;60(13):5717-5735. doi: 10.1021/acs.jmedchem.7b00425. Epub 2017 Jun 30. J Med Chem. 2017. PMID: 28621538
A Randomized, Controlled Phase I/II Study to Evaluate the Safety and Efficacy of MGV354 for Ocular Hypertension or Glaucoma.
Stacy R, Huttner K, Watts J, Peace J, Wirta D, Walters T, Sall K, Seaman J, Ni X, Prasanna G, Mogi M, Adams C, Yan JH, Wald M, He Y, Newton R, Kolega R, Grosskreutz C. Stacy R, et al. Among authors: newton r. Am J Ophthalmol. 2018 Aug;192:113-123. doi: 10.1016/j.ajo.2018.05.015. Epub 2018 May 24. Am J Ophthalmol. 2018. PMID: 29802818 Clinical Trial.
Improving weight loss and cardiometabolic risk in black patients with diabetes or pre-diabetes: Rationale and protocol for a digital medicine hybrid type 1 implementation trial.
Katzmarzyk PT, Price-Haywood EG, Apolzan JW, Denstel KD, Drews KL, Farris E, Harden-Barrios J, Hearld LR, Mire EF, Martin CK, Newton RL, Pisu M. Katzmarzyk PT, et al. Among authors: newton rl. Contemp Clin Trials. 2025 Jan 3;149:107806. doi: 10.1016/j.cct.2024.107806. Online ahead of print. Contemp Clin Trials. 2025. PMID: 39756673
Multi-methods process evaluation of the SToP (See, Treat, Prevent) trial: a cluster randomised, stepped wedge trial to support healthy skin.
Thomas HMM, Mullane M, Enkel SL, McRae T, Amgarth-Duff I, Carapetis JR, Coffin J, Christophers R, Famlonga R, Jacky J, Jones M, Marsh J, McIntosh K, O'Donnell V, Pan E, Pearson G, Sibosado S, Smith B, Snelling T, Steer A, Tong SYC, Walker R, Whelan A, White K, Wright E, Bowen AC; SToP (See, Treat, Prevent skin sores and scabies) Trial. Thomas HMM, et al. EClinicalMedicine. 2024 Oct 9;77:102793. doi: 10.1016/j.eclinm.2024.102793. eCollection 2024 Nov. EClinicalMedicine. 2024. PMID: 39649132 Free PMC article.
Meeting Aerobic Physical Activity Guidelines and Associations With Physical Fitness in Men With Metastatic Prostate Cancer: Baseline Results of the Multicentre INTERVAL-GAP4 Trial.
Umlauff L, Kenfield SA, Newton RU, Hart NH, Saad F, Courneya KS, Greenwood R, Bloch W; INTERVAL‐GAP4 Steering Committee/Coordinating Centres Members/Protocol Development Working Group Members; Schumann M. Umlauff L, et al. Among authors: newton ru. Cancer Med. 2024 Dec;13(23):e70261. doi: 10.1002/cam4.70261. Cancer Med. 2024. PMID: 39632499 Free PMC article.
2,126 results